Just over a decade ago Ernesto
Freire suggested that small molecules whose binding energy is dominated by the
enthalpic – rather than the entropic – term make superior drugs. He also
suggested that such molecules may be more selective for their target. But the
backlash came quickly, and a couple years ago we wrote that focusing on
thermodynamics probably isn’t particularly practical. A new perspective in Drug Disc. Today by Gerhard Klebe
(Philipps-University Marburg) revisits this topic.
Klebe suggests that enthalpy was
initially embraced “because readily accessible and easily recordable parameters
are much sought after for the support of the nontrivial decision over which molecules
to take to the next level of development.” (I would be interested to know
whether sales of isothermal titration calorimetry (ITC) instruments spiked
around 2010.) Unfortunately, both theoretical and practical reasons make thermodynamic
measurements less useful than hoped.
First, and as we noted
previously, “in an ITC experiment… the balance sheet of the entire process is
measured.” In particular, water molecules – which make up the bulk of the
solution – can affect both enthalpic and entropic terms. Klebe describes an
example in which the most flexible of a series of ligands binds with the most
favorable entropy to the target protein; this is counterintuitive because the
ligand adopts a more ordered state once bound to the protein. It turned out
that in solution the ligand traps a water molecule that is released when the
ligand binds to the protein, thus accounting for the favorable entropy.
Indeed, water turns out to be a major
confounding factor. We’ve previously written about “high-energy” water; Klebe
notes that an individual water molecule can easily contribute more than 2
kcal/mol to the overall thermodynamic signature. And of course, proteins in
solution are literally bathed in water. The structure of this water network,
which may change upon ligand binding, is rarely known experimentally, but optimizing
for it can improve affinity of a ligand by as much as 50-fold. Conversely, attaching
a polar substituent to a solvent-exposed portion of a molecule to improve
solubility sometimes causes a loss in affinity, and Klebe suggests this can be due
to disruption of the water sheath.
Beyond these theoretical considerations,
experimental problems abound. We’ve previously discussed how spurious
results can be obtained when testing mixtures of ligands in an ITC experiment,
but even with single protein-ligand complexes things can get complicated. Klebe
shows examples where the relative enthalpic and entropic components to free
energy change dramatically simply because of changes in buffer or temperature.
This means that the growing body of published thermodynamic data needs to be
treated cautiously.
So what is to be done? First,
thermodynamic data should always be treated relatively: “we should avoid
classifying ligands as enthalpy- or entropy-driven binders; in fact, we can only
differentiate them as enthalpically or entropically more favored binders
relative to one another.”
Klebe argues that collecting data
on a variety of ligands for a given target under carefully controlled
conditions will be useful for developing computational binding models. This is
important, but not the kind of work for which people usually win grants, let
alone venture funding.
He also suggests that, by
collecting thermodynamic data across a series of ligands, unexpected changes in
thermodynamic profiles might reveal “changes in binding modes, protonation
states, or water-mediated interactions.” Maybe. But it takes serious effort to
collect high-quality ITC data. Are there examples where you’ve found it to be
worthwhile?
I love that "but not the kind of work for which people usually win grants".
ReplyDeletePutting data into relative perspective should also be important for other (biophysical) assays. We use ITC mainly as an orthogonal tool to verify results from SPR/NMR and rarely look at enthalpy/entropy.